1. Introduction {#sec1-pathogens-08-00212}
===============

Since the first New Delhi metallo-*β*-lactamase 1 (*bla*~NDM-1~) was identified from a carbapenem-resistant *Klebsiella pneumoniae* strain \[[@B1-pathogens-08-00212]\], several variations of this metallo-β-lactamase have been discovered all over the world. One variant, *bla*~NDM-9~, was identified from a *K. pneumoniae* clinical isolate in China \[[@B2-pathogens-08-00212]\]. Accompanying the rise of carbapenem-resistant bacteria, colistin has become used more commonly, despite its serious side effects. Under the selective pressure of colistin, the first *bla*~NDM-9~ and *mcr-1* co-harboring *E. coli* ST167 strain was identified from a retail chicken in 2016 \[[@B3-pathogens-08-00212]\]. Subsequent thereto, *E. coli* strains co-harboring *bla*~NDM-9~ and *mcr-1* were reported from a chicken farm in China \[[@B4-pathogens-08-00212]\]. Since then, there have been concerns over the spread of this strain to humans. A *bla*~NDM-9~ and *mcr-1* co-harboring *E. coli* 5CRE51 strain from a urine sample was first reported in Taiwan in 2017 \[[@B5-pathogens-08-00212]\]. This strain carried two different plasmids that harbored *bla*~NDM-9~ and *mcr-1* and belonged to the ST617 strain \[[@B6-pathogens-08-00212]\]. Recently, a *bla*~NDM-9~ and *mcr-1* co-harboring *E. coli* isolate was identified from an asymptomatic carrier in Korea in a retrospective study. Subsequent thereto, phenotypic and phylogenomic analyses were conducted to trace the strain's origin.

2. Case Report {#sec2-pathogens-08-00212}
==============

An 81-year-old female was admitted to a university hospital in February 2017 for aortic cardiac valve repair surgery. The patient had chest pain and dyspnea on exertion that had been aggravated six months before a diagnosis of severe aortic regurgitation. The patient had no history of abroad travel, visiting a farm or any signs of infections. She received preoperative antibiotic prophylaxis with amoxicillin-clavulanate. Following surgery, she was admitted to the intensive care unit (ICU) for three days, and carbapenem-resistant *E. coli* YMC/2017/02/MS631 was isolated from a rectal swab surveillance culture, which was routinely performed to stop the spreading of *Klebsiella pneumoniae* carbapenemase-producing Enterobacteriaceae in the ICU. Antimicrobial susceptibility testing (AST) for colistin was not performed at that time. Upon retrospective study, colistin resistance was detected: In vitro AST was performed using both broth microdilution and agar dilution methods. The results were interpreted according to the Clinical and Laboratory Standards Institute guidelines \[[@B7-pathogens-08-00212]\], with the exception of tigecycline and colistin, for which the European Committee on Antimicrobial Susceptibility Testing v9.0 was applied (<http://www.eucast.org/clinical_breakpoints/>). The isolate was resistant to all tested antibiotics (amoxicillin-clavulanic acid, piperacillin, piperacillin-tazobactam, cefotaxime, ceftazidime, cefepime, cefoxitin, aztreonam, ertapenem, meropenem, imipenem, ceftazidime-avibactam, amikacin, gentamicin, ciprofloxacin, trimethoprim-sulfamethoxazole, and colistin), except for tigecycline ([Table 1](#pathogens-08-00212-t001){ref-type="table"}).

Whole genomic DNA was extracted and sequenced using an Illumina Hiseq2500^TM^ (Illumina, Valencia, CA, USA). Sequence reads were assembled using SPAdes version 3.12 \[[@B8-pathogens-08-00212]\]. The genome was annotated employing Rapid Annotation using Subsystem Technology \[[@B9-pathogens-08-00212]\] and deposited in the NCBI GenBank with the accession number SBHK00000000. Resistance genes, serotype, multi-locus sequence type (MLST), plasmid replicon type, and virulence factors were analyzed using ResFinder 3.1 \[[@B10-pathogens-08-00212]\], SeroTypeFinder 2.0 \[[@B11-pathogens-08-00212]\], MLST 2.0 \[[@B12-pathogens-08-00212]\], PlasmidFinder 2.0 \[[@B13-pathogens-08-00212]\], and VirulenceFinder 2.0 \[[@B14-pathogens-08-00212]\], respectively. Despite sharing the same sequence type (ST617) and serotype (O89/162: H10) with *E. coli* 5CRE51 \[[@B6-pathogens-08-00212]\], this strain carried additional resistance genes, namely, *bla*~TEM-1B~, *bla*~CTX-M-55~, *aph(3')IIa, aph(3')Ib, rmtB, aph(6)-Id, oqxA, oqxB, mph(A), mdf(A),* and *sul2,* accounting for cephalosporin, aminoglycoside, fluoroquinolone, macrolide, and sulfamethoxazole resistance ([Table 1](#pathogens-08-00212-t001){ref-type="table"}). Additionally, the *mcr-1* sequence from *E. coli* YMC/2017/02/MS631 had one silent mutation at position 1074 (C→A), compared with a previously reported *mcr-1*. Seven plasmid replicon types (IncB, IncFII, IncI2, IncN, IncY, IncR, IncX1), and two virulence factors (*gad*, *iss*) were identified. Transferability of the *bla*~NDM-9~ and *mcr-1* genes was achieved by conjugation experiments with *E. coli* J53 as the recipient strain \[[@B15-pathogens-08-00212],[@B16-pathogens-08-00212]\]. Transconjugants were selected on Mueller--Hinton agar plates containing 100 μg/mL of sodium azide with 4 μg/mL of imipenem or 2 μg/mL of colistin. Resistance genes and plasmid replicon types in the transconjugants were identified by PCR and Sanger sequencing using designed primers ([Table S1](#app1-pathogens-08-00212){ref-type="app"}). The transconjugant *E. coli* EJ533 was susceptible to all tested antibiotics but colistin and harbored *mcr-1* on the IncI2 type plasmid. Meanwhile, the transconjugant *E. coli* EJ5331 was resistant against all β-lactams but aztreonam and carried *bla*~NDM-9~ and other resistance genes (*aadA2*, *fosA3, mph(A), sul2, and dfrA12)* on the IncB type plasmid ([Table 1](#pathogens-08-00212-t001){ref-type="table"}).

The relatedness of *E. coli* 5CRE51 and YMC/2017/02/MS631 in the context of worldwide *E. coli* ST617 distribution was investigated using EnteroBase database (<http://enterobase.warnick.ac.uk/>) ([Figure 1](#pathogens-08-00212-f001){ref-type="fig"}). Altogether, 200 *E. coli* ST617 strains among 82,737 *E. coli* genomes (0.24%) have been reported in EnteroBase with the key words "*E. coli*" and "ST617" at the time of writing this paper ([File S1](#app1-pathogens-08-00212){ref-type="app"}). *E. coli* ST617 strains have been detected in at least 31 countries and from different sources, including human, animal, and environmental samples ([Figure S1, S2A](#app1-pathogens-08-00212){ref-type="app"}). Among them, 170 *E. coli* genomes were accessible for analysis ([File S1](#app1-pathogens-08-00212){ref-type="app"}). Thirteen different serotypes were identified from the collected genomes. Considering 170 genomes, 82 (48.2%) belonged to serotype O89/162: H10 ([Figure S2B](#app1-pathogens-08-00212){ref-type="app"}) and were included in the phylogenomic tree constructed using CSI phylogeny 1.4 \[[@B17-pathogens-08-00212]\]. The phylogenetic tree was visualized using iTOL (<https://itol.embl.de/>) and indicated that *E. coli* YMC/2017/02/MS631 was distant from *E. coli* 5CRE51 and other strains. The closest strains were detected in Poland (ESC_IA1353AA) and Germany (ESC_IA2276AA) ([Figure 1](#pathogens-08-00212-f001){ref-type="fig"}). Meanwhile, *E. coli* 5CRE51 belonged to a clade with strains collected from Oman (ESC_EA6169AA) and The Netherlands (ESC_EA9479AA). This suggested that the two strains emerged independently.

3. Discussion {#sec3-pathogens-08-00212}
=============

The first *bla*~NDM-9~ and *mcr-1* co-harboring *E. coli* isolate belonged to a ST167 strain was followed by ST10 complexes, ST101, ST156, and ST297 \[[@B3-pathogens-08-00212],[@B4-pathogens-08-00212]\]. The primary source was chicken meat. This strain rarely has been reported in clinical settings. Our report is important because it was detected coincidentally in a retrospective cohort study, and the strain displayed high antibiotic resistance with complicated plasmid types. Additionally, this strain displayed a broader resistance spectrum than the *E. coli* 5CRE51 isolate from Taiwan. Furthermore, the strain had two- and eight-folds higher minimal inhibitory concentrations (MICs) for meropenem and imipenem and an eight-fold higher MIC for amikacin in comparison with *E. coli* 5CRE51. However, the colistin MIC was the same: 4 μg/mL \[[@B5-pathogens-08-00212]\]. Resistome profiles, plasmid typing, and whole-genome phylogenetic tree analyses suggested that the two strains were not closely related. Interestingly, *E. coli* ST617 has mainly been detected in European countries, the United States, and China, and only two isolates of *E. coli* ST617 have been reported for Taiwan and Korea, according to EnteroBase ([Figure S2A](#app1-pathogens-08-00212){ref-type="app"}). The dominance of E. coli ST617 serotype O89/162:H10 among 13 serotypes may suggest that *E. coli* ST617 serotype O89/162: H10 can be a potential reservoir for *bla*~NDM-9~ and *mcr-1* co-harboring *E. coli* in clinical settings.

According to the EUCIC medical guidelines on decolonization \[[@B18-pathogens-08-00212]\], there is a lack of evidence regarding the efficiency of decolonization for multidrug-resistant gram-negative organisms in hospitalized patients. Hence, the patient can be discharged without any treatment or intervention for decolonization. This may, in turn, lead to a silent continuous spread of this strain in the population at large. Additionally, travel by asymptomatic *bla*~NDM-9~ and *mcr-1* carriers could facilitate strain transmission. A recent study emphasized the contribution of fecal pollution to an abundance of resistance genes in effluent-receiving environments \[[@B19-pathogens-08-00212]\]. Routine rectal swab screening to identify asymptomatic colistin and/or carbapenem-resistance carriers might be warranted to control the spread of multi-drug resistant organisms in hospital settings.

4. Conclusions {#sec4-pathogens-08-00212}
==============

To the best of our knowledge, this is the first report of resistome profiles, plasmid typing, and whole-genome phylogenetic tree analyses of a *bla*~NDM-9~ and *mcr-1* co-harboring *E. coli* strain isolated from an asymptomatic carrier. Moreover, the resistance genes were transferable to azide-resistant *E. coli* J53. Further surveillance studies should be conducted to detect the prevalence of this strain among health-care systems in Korea.
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###### 

Characterization of *mcr-1*, *bla*~NDM-9~, and *bla*~CTX-M-55~-positive *E. coli* YMC/2017/02/MS631 and its transconjugants.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameters                      *E. coli*\                                                                                                                                             Transconjugants                                              
                                  YMC/2017/\                                                                                                                                                                                                          
                                  02/MS631                                                                                                                                                                                                            
  ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------- ------------------------------------------ ----------------
  Source                          Asymptomatic carrier                                                                                                                                   \-                \-                                         \-

  Isolation site                  Rectal swab                                                                                                                                            \-                \-                                         \-

  Resistance genes                *bla*~NDM-9~,\                                                                                                                                         *mcr-1*           *bla*~NDM-9~, *aadA2*, *fosA3, mph(A),*\   \-
                                  *bla*~CTX-M-55~, *bla*~TEM-1B~, *aph(3')IIa, aph(3')Ib, rmtB, aph(6)-Id, aadA2, oqxA, oqxB, fosA3, mph(A), mdf(A),floR, sul2, tet(A), dfrA12, mcr-1*                     *dfrA12*                                   

  MLST                            617                                                                                                                                                    \-                \-                                         \-

  Serotype                        O89/162:H10                                                                                                                                            \-                \-                                         \-

  Plasmid replicon type(s)        IncB, IncFII, IncI2, IncN, IncY, IncR, IncX1                                                                                                           IncI2             IncB                                       \-

  Virulence factors               *gad*, *iss*                                                                                                                                                                                                        

  *ompC, ompF*                    Intact                                                                                                                                                                                                              

  MIC (μg/mL, interpretation)                                                                                                                                                                                                                         

  Amoxicillin-clavulanic acid     128, R ^†^                                                                                                                                             4, S ^‡^          8, R ^‡^                                   4, S ^‡^

  Piperacillin                    ≥256, R ^†^                                                                                                                                            N/D               N/D                                        N/D

  Piperacillin-tazobactam         ≥256, R ^†^                                                                                                                                            ≤4, S ^‡^         ≥128, R^‡^                                 ≤4, S ^‡^

  Cefotaxime                      ≥256, R ^†^                                                                                                                                            ≤1, S ^‡^         ≥64, R ^‡^                                 ≤1, S ^‡^

  Ceftazidime                     ≥256, R ^†^                                                                                                                                            ≤1, S ^‡^         ≥64, R ^‡^                                 ≤1, S ^‡^

  Cefepime                        ≥256, R ^†^                                                                                                                                            ≤1, S ^‡^         ≥64, R ^‡^                                 ≤1, S ^‡^

  Cefoxitin                       ≥256, R ^†^                                                                                                                                            8, S ^‡^          32, R ^§^                                  ≤1, S ^‡^

  Aztreonam                       ≥128, R ^†^                                                                                                                                            ≤1, S ^‡^         ≤1, S ^‡^                                  ≤1, S ^‡^

  Ertapenem                       64, R ^†^                                                                                                                                              ≤0.5, S ^‡^       4, R ^‡^                                   ≤0.5, S ^‡^

  Meropenem                       16, R ^†^                                                                                                                                              N/D               N/D                                        N/D

  Imipenem                        32, R ^†^                                                                                                                                              ≤0.25, S ^‡^      8, R ^‡^                                   ≤0.25, S ^‡^

  Ceftazidime-avibactam           ≥256, R ^†^                                                                                                                                            N/D               N/D                                        N/D

  Colistin                        4, R ^‡^                                                                                                                                               4, R ^‡^          ≤0.125, S ^‡^                              \<0.125, S ^‡^

  Amikacin                        ≥16, R ^‡^                                                                                                                                             ≤2, S ^‡^         ≤2, S ^‡^                                  ≤2, S ^‡^

  Gentamicin                      ≥16, R ^‡^                                                                                                                                             ≤1, S ^‡^         ≤1, S ^‡^                                  ≤1, S ^‡^

  Ciprofloxacin                   ≥4, R ^‡^                                                                                                                                              ≤0.25, S ^‡^      ≤0.25, S ^‡^                               ≤0.25, S ^‡^

  Tigecycline                     0.5, S ^‡^                                                                                                                                             ≤0.5, S ^‡^       ≤0.5, S ^‡^                                ≤0.5, S ^‡^

  Trimethoprim-sulfamethoxazole   320, R ^‡^                                                                                                                                             ≤20, S ^‡^        ≤20, S ^‡^                                 ≤20, S ^‡^
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: MIC, minimal inhibitory concentration; MLST, Multi Locus Sequence Type; N/D, not determined. In vitro antimicrobial susceptibility testing was performed using an agar dilution method † and a broth microdilution method ^‡^ following the Clinical and Laboratory Standards Institute (CLSI) guidelines M100 28th ed. MIC interpretations followed CLSI M100 28th ed, with the exception of tigecycline and colistin, for which the European Committee on Antimicrobial Susceptibility Testing guidelines v9.0 were applied.
